2,172 results on '"Peyrin-Biroulet, L"'
Search Results
2. AB1410 EARLY SYMPTOMATIC IMPROVEMENT WITH GUSELKUMAB INDUCTION TREATMENT IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
3. Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy
4. Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus
5. OC.13.2: EARLY HISTO-ENDOSCOPIC RESPONSE PREDICTS CLINICAL OUTCOMES WITH MIRIKIZUMAB IN ULCERATIVE COLITIS LUCENT TRIALS
6. OC.03.8: EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHN'S DISEASE: 104-WEEK EXTENSION RESULTS FROM A PHASE 2 RANDOMIZED CONTROLLED TRIAL
7. Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease.
8. P927 Long-term outcomes of risankizumab in Crohn’s disease: a multicenter GETAID Study
9. P772 Comprehensive disease control in patients with Ulcerative Colitis: refinement of a multi-component endpoint using data from the filgotinib SELECTION trial
10. DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial
11. OP05 Primary efficacy and safety of mirikizumab in moderate to severe Crohn’s Disease: results of the treat-through VIVID 1 study
12. P051 Diets enriched in fat and sugar and sex-dependant response to colitis in a mouse model
13. P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel Diseases
14. P593 Efficacy of Risankizumab in Patients With Moderately to Severely Active Ulcerative Colitis by Prior Advanced Therapy Failure and Mechanism of Action: Post Hoc Analysis of the INSPIRE and COMMAND Phase 3 Studies
15. DOP71 Efficacy of once-daily, orally administered obefazimod in patients with moderately to severely active UC at weeks 8, 48, and 96 broken down by induction treatment dose
16. P571 The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to Human
17. P857 Effectiveness and safety of subcutaneous infliximab in perianal Crohn's disease: a multicentre cohort study
18. P280 Comparative responsiveness of disease activity indices in moderately-to-severely active Ulcerative Colitis: a post-hoc analysis of the UNIFI trial
19. P225 Mucosal transcriptomic profiles associated with clinical response in patients with Ulcerative Colitis receiving filgotinib
20. DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial
21. P710 Prevalence, Characteristics and Management of Patients with Difficult-To-Treat Inflammatory Bowel Disease: A Cross-Sectional Study From a Tertiary Referral Center
22. P1071 Patient preferences for adalimumab in inflammatory bowel disease: a nationwide study from the GETAID
23. P430 The influence of persistent organ damage on IFX pharmacokinetic modeling and disease progression assessment: findings from a prospective real-world study in inflammatory bowel disease patients
24. OP06 Risankizumab Maintenance Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: Efficacy and Safety in the Randomised Phase 3 COMMAND Study
25. DOP65 Infliximab plus azathioprine and quick steroids discontinuation versus azathioprine plus steroids in patients with acute severe Ulcerative Colitis responding to intravenous steroids: a parallel, open-label randomized controlled trial
26. P1013 Placebo rates in Crohn's disease: An individual patient data meta-analysis from multiple randomised controlled trials
27. OP12 Mirikizumab improves fatigue, bowel urgency, and quality of life in patients with moderately to severely active Crohn’s Disease: Results from a phase 3 clinical trial
28. P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial
29. P1010 Guselkumab improves abdominal pain and bowel urgency symptoms in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
30. P903 Persistence, efficacy and tolerance of subcutaneous Infliximab after switch from intravenous infliximab in IBD patients in remission: one-year results from a multicenter prospective cohort
31. P683 Economic impact of achieving mucosal healing on UC-related hospitalisations and work productivity in patients with moderately to severely active UC: A post-hoc analysis of risankizumab Phase 2b/3 trials
32. DOP12 Efficacy and safety of obefazimod in UC patients at weeks 48 and 96 of an open-label maintenance study among clinical responders at week 8 of the Phase 2b induction trial
33. DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial
34. OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a randomised, double-blind, placebo-controlled, phase 2 trial
35. P985 Efficacy and safety of de-escalation from 50 mg to 25 mg of oral, once-daily, obefazimod for the third and fifth year of open-label maintenance treatment in patients with moderately to severely active ulcerative colitis (UC): An interim analysis
36. P678 Long-term efficacy, safety and health-related quality of life in patients who achieved comprehensive disease control with filgotinib in SELECTION: analysis of ~3 years in SELECTIONLTE
37. P931 Burden of disease among Ulcerative Colitis patients with isolated proctitis in the United States and Europe
38. P1036 Persistence of biologics and advanced small molecules in 4th, 5th and 6th line of therapy for inflammatory bowel disease: a cross-sectional retrospective study
39. P524 Etrasimod shows low risk of adverse events following concomitant use with opioids or antidepressants in patients with ulcerative colitis
40. P114 Role of NLRX1 Agonist NX-13 in Reducing Visceral Hypersensitivity in Preclinical Gastrointestinal Inflammation
41. P954 Cumulative response to guselkumab through week 24 of induction in patients with moderately to severely active ulcerative colitis: Results from the phase 3 QUASAR induction study
42. P752 Difficult-to-treat inflammatory bowel disease: effectiveness and safety of 4th and 5th lines
43. Non-invasive monitoring and treat-to-target approach are cost-effective in patients with mild–moderate ulcerative colitis
44. AB1826-HPR HOW TO ASSESS THE SATISFACTION OF PATIENTS WITH CHRONIC INFLAMMATORY DISEASES AFTER SWITCHING TO A BIOSIMILAR? INSIGHTS FROM AN EXPLORATORY QUALITATIVE STUDY PRELIMINARY TO AN OBSERVATIONAL STUDY
45. Ulcerative proctitis: Challenges for clinical management
46. CO2.1 - Utilisation de messages de patients postés sur un forum internet pour développer un questionnaire de mesure des poussées de la maladie dans les MICI
47. Endoscopic Submucosal Dissection in Inflammatory Bowel Disease Patients for Visible Dysplasia: a French Retrospective Multicentric Study
48. OC.04.4 ULTRASOUND REMISSION AFTER BIOLOGIC INDUCTION PREDICTS LONG-TERM ENDOSCOPIC REMISSION IN CROHN'S DISEASE
49. A186 ASSOCIATION OF ULCERATIVE COLITIS BOWEL URGENCY IMPROVEMENT WITH CLINICAL RESPONSE AND REMISSION
50. OC.03.3 MOLECULAR AND MICROBIOTA PROFILING IN EOSINOPHILIC ESOPHAGITIS: A TRANSCRIPTOME AND META-TRANSCRIPTOME META-ANALYSIS
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.